Hershey and Vertex flash death crosses as analysts see 20% upside

Death crosses flashed on Hershey and Vertex this week, yet analyst consensus targets imply 20% to 23% upside on both stocks.

"The technical signal is mechanically valid but informationally weak," said an analyst at a bulge-bracket firm who requested anonymity because they are not authorized to speak publicly. "The separation between the moving averages is less than a dollar on both names."

Hershey closed at $180.84 on June 11, with its 50-day moving average at $193.09 versus the 200-day at $193.97 — a gap of $0.88. Vertex's 50-day stood at $436.72 against a 200-day of $437.41, a $0.69 spread. The consensus price target on Hershey is $217.14, while Vertex's is $548.69.

The divergence between the bearish chart patterns and bullish Wall Street consensus creates a potential entry point. Vertex's povetacicept BLA for IgA nephropathy is under a six-month FDA Priority Review, a near-term catalyst the technicals do not reflect. Hershey trades at 21 times forward earnings with a 3.2% dividend yield.

Hershey's fundamentals support the analyst view. The confectioner delivered Q1 FY2026 adjusted EPS of $2.35, a 14.67% beat over the $2.05 estimate. Revenue totaled $3.10 billion after growing 10.65% year over year. Management reaffirmed FY2026 guidance for adjusted EPS of $8.20 to $8.52, implying low-double-digit growth for the full year. Of 24 analysts covering the stock, four rate it Strong Buy, five say Buy, 14 rate it Hold and one says Sell. The trailing P/E of 33 reflects earnings normalization from pandemic-era highs, while the forward multiple of 21 and beta of 0.081 make it one of the lowest-volatility names in consumer defensive coverage.

Vertex's pipeline diversification is gaining traction. The biotech firm posted Q1 2026 non-GAAP EPS of $4.47 against a $4.31 estimate, with operating income up 80.62% year over year. Non-CF products contributed more than 25% of quarterly growth, validating the diversification thesis beyond its core cystic fibrosis franchise. Cash reached $7.247 billion, up 55.02% year over year. The rating split is overwhelmingly bullish: six Strong Buy, 21 Buy, five Hold and one Sell among 33 analysts. The stock has already started recovering, up 2.1% on the most recent session, while the slower 200-day moving average catches down.

Institutional ownership of 88% for Hershey and 98% for Vertex indicates professional investors have not exited positions in any significant size. Both stocks trade well below their 52-week highs — Hershey at $239.48 and Vertex at $507.92.

The bullish consensus faces one clear risk: a fresh negative catalyst could extend the downtrend on either name. But on the weight of current evidence, the bearish chart pattern is the noisier signal, and the analyst consensus is the cleaner one. Investors will watch Vertex's FDA decision on povetacicept, expected within six months, and Hershey's Q2 earnings report for continued execution against guidance.

This article is for informational purposes only and does not constitute investment advice.